Johnson & Johnson Settles Marketing Charges

Nov 5, 2013
Originally published on November 5, 2013 5:08 am

Johnson & Johnson became the latest drugmaker to reach a costly agreement with the federal government over charges of improper marketing. The widely anticipated settlement, unveiled Monday, covers Natrecor, a drug for congestive heart failure, and antipsychotics Risperdal and Invega.